About us

ATGen Canada Inc. is an immunodiagnostic company focused on the development of in vitro diagnostic devices for the analysis of patients’ immune function. Immunosurveillance performed by lymphoid cells is important in immunity against foreign antigens and tumor cells.

ATGen Canada Inc. is subsidiary of ATGen Co Ltd., a company founded in 2002 in South Korea. ATGen Co Ltd. Is a biotech company that manufactures and supplies a wide array of recombinant proteins and antibodies worldwide. ATGen’s proprietary stable protein technology has enabled the company to expand into the development of in vitro diagnostic devices, several of which are under development for immune system monitoring.

Our Team

 

 

 

Dr. Katia Betito, Ph.D. – President

Dr. Betito has over 20 years of experience in scientific affairs including regulatory affairs, clinical research and drug development. Prior to joining ATGen Canada Inc., Dr. Betito was a consultant in regulatory affairs for pharmaceutical, medical device, natural health product and cosmetic companies, helping with strategic guidance, regulatory submissions, provincial reimbursement submissions and medical writing. Prior to this, Dr. Betito was Executive Director of Scientific Affairs for Paladin Labs, responsible for regulatory affairs, quality control, clinical research, medical information and drug development. Dr. Betito has also served as Director Regulatory Affairs at Sabex Inc. (now Sandoz, a division of Novartis) holding similar responsibilities. Dr. Betito received her B.Sc. in Physiology and a Ph.D. in Pharmacology both from McGill University, Montreal.

 

 

Dr. Roberto Rodriguez-Suarez, Ph.D. – Senior Manager, Medical and Scientific Affairs

Dr. Rodriguez-Suarez brings an extensive academic and industry experience in cellular and molecular biology, biochemistry, protein science, and reagents development. Prior to joining ATGen Canada Inc., Dr. Rodriguez-Suarez was Technical Project Leader at PerkinElmer R&D, where he had central responsibilities in generating the reagents portfolio for Epigenetics research. He has also been a Senior Research Biologist in the Department of Infectious diseases at Merck, and a Senior Scientist and R&D Group Leader at Amega Biotech in Argentina. His post-doctoral experience includes performing research at McGill and Yale Universities. Dr. Rodriguez-Suarez received his B.Sc. in Biological Sciences and his Ph.D. in Biochemistry and Molecular Biology from University of Buenos Aires, Argentina.

 
 

 

Andrea Herrera-Gayol, MD, M.Sc., Ph.D. – Medical Director

Dr. Herrera-Gayol has several years of experience as a physician/scientist, and scientific consultant in medical science; and medical education and communications. In the biotechnology and pharmaceutical industries, she played key roles in applied research (oncology), business development (oncology, rare diseases, diabetes, neurology and diagnostics) and medical affairs (oncology, neurology, and rare diseases). She has collaborated with Canadian and International medical societies, universities and medical education companies in the development of educational programs in oncology, neurology, immunology, transplantation, and nephrology. She received her MD from U. de Buenos Aires (Argentina), her MSc from U. de Montreal (Canada) and her PhD from McGill (Canada).